UPDATE: SVB Leerink On Inogen Price Target Cut: Firm Sees Potential But Remains 'On The Sidelines Pending Further Clarity On The Timing' Towards 65% Penetration Of Oxygen Therapy Market; Warns Chip Shortages To Limit Co.'s Ability To Meet End-User Demand